1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Physician Views: Have expectations been reset for Puma Biotechnology's neratinib in HER2+ breast cancer?

Physician Views: Have expectations been reset for Puma Biotechnology's neratinib in HER2+ breast cancer?

  • May 2015
  • ID: 3090963
  • Format: PDF
  • By Firstword Pharma

Summary






Investors appear to be resetting their expectations for Puma Biotechnology's experimental HER2-positive breast cancer treatment neratinib. An abstract released last week – ahead of this year's ASCO annual meeting (May 29 – June 2) – indicates that neratinib's superiority versus placebo in 'extended adjuvant' patients (those treated with neratinib following 12 months of adjuvant therapy with Herceptin) is not as pronounced as expected (ViewPoints: As the ASCO abstract dump claims its biggest casualty, Puma Biotechnology CEO argues for a reprieve).

An absolute difference of 2.3 percent in favour of the neratinib arm – 93.9 percent of patients achieved invasive disease-free survival (DFS) at two years versus 91.6 percent of patients in the control arm – prompted Puma's shares to decline by around 20 percent.

As discussed here, Puma's disclosure nearly a year ago that neratinib had achieved a hazard ratio of 0.67 in the ExteNET study raised expectations significantly, both among investors and physicians polled by FirstWord, as well as among analysts who have frequently touted Puma as a likely large-cap acquisition target.

The new data suggest these expectations will need to be revised, particularly when the efficacy demonstrated by neratinib is considered alongside its side-effect profile and high rates of grade 3 diarrhoea.

Even prior to recent publication of the ASCO abstract, which has raised question marks over efficacy benefit in the extended adjuvant setting, key opinion leaders (KOLs) interviewed by FirstWord for a forthcoming report on the breast cancer landscape (for more details click HERE) cited neratinib's side-effect profile as a preclusion to widespread use. They instead suggest that if approval is secured, it is likely to be as a third- or fourth-line 'salvage therapy' used in the metastatic setting.

Puma CEO Alan Auerbach has suggested that the prognosis for neratinib should improve when further data is presented at ASCO. Only locally confirmed HER2 positivity was required for enrolment in the ExteNET study and around 80 percent of these patients were subsequently confirmed to be HER2 positive upon central testing. Thus the absolute difference in DFS between the neratinib and control arms should widen, argues Auerbach, with analysts at Leerink suggesting it could expand to around 4.5 percent. Furthermore, they argue that any "further improvement of over 4 percent in disease-free survival with 1 year of neratinib over a 6 percent improvement from the current standard care of 1 year of Herceptin to be highly clinically significant."

A notable read across from the abstract is just how effective Herceptin is at treating HER2-positive breast cancer, argue analysts at Stifel; a view backed up by a chorus of KOL opinion in FirstWord's new Therapy Trends report.

A key point of debate around the commercial opportunity for neratinib is tied to Roche's ongoing study of Herceptin and Perjeta in the adjuvant setting (in the APHINITY study) as a means of potentially enhancing Herceptin's efficacy profile, which KOLs indicate has a high chance of success. Auerbach has played down the significance of the APHINITY study as neratinib's potential use in the 'extended adjuvant' indication (i.e. after 12 months Herceptin or Herceptin/Perjeta therapy) represents a distinct setting.

Roche's ability to enhance the treatment paradigm for adjuvant patients may also be shaped by results from the KATHERINE study, where Kadcyla is being assessed head-to-head versus Herceptin. KOLs are more sceptical towards a positive result from this trial, however, given publication of disappointing top-line data from the MARIANNE study in December.






To better ascertain the impact of new data for neratinib and ongoing studies being run by Roche in the adjuvant setting, we are asking US and EU5-based oncologists the following questions…


Based on updated efficacy data from the ExteNET study and factoring in that 40 percent of patients in the trial suffered serious diarrhoea, what impact would you expect neratinib to have in the clinical setting for the treatment of 'extended adjuvant' patients?
Assuming that the absolute difference in DFS between the neratinib and control arms was 4 percent or higher (based on reassessment of HER2 positivity), what impact would you expect neratinib to have in the clinical setting for the treatment of 'extended adjuvant' patients?
If the combination of Herceptin and Perjeta is shown to improve DFS (primary endpoint) and overall survival (secondary endpoint) versus Herceptin alone in the ongoing APHINITY study, would you expect this to also limit use of neratinib in the extended adjuvant setting?
What is your opinion towards this statement…'if approved, neratinib will likely end up in the metastatic setting as a salvage therapy'?
Based on the entrenchment of Herceptin, your experience of using Kadcyla and top-line data from the MARIANNE study (when Kadcyla plus Perjeta was not shown to be superior to Herceptin plus Perjeta in first-line patients), what are your expectations for Kadcyla in the adjuvant setting (currently being trialled versus Herceptin in the KATHERINE study)?




Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2015

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on